SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Evofem Biosciences, Inc. (OTC – EVFM)

BALA CYNWYD – December 12, 2023 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Evofem Biosciences, Inc. (“Evofem” or the “Company”) (OTC – EVFM) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Aditxt, Inc. (“Aditxt”) (Nasdaq – ADTX). Under the terms of the agreement, Aditxt will acquire Evofem in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million.

The investigation concerns whether the Evofem Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Aditxt is paying fair value to shareholders of the Company.

If you own shares of Evofem stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.